Your browser doesn't support javascript.
loading
Effect of medroxyprogesterone acetate dose in progestin-primed ovarian stimulation on pregnancy outcomes in poor ovarian response patients with different body mass index levels.
Zhang, Qianjie; He, Shaojing; Meng, Yicen; Yin, Tailang; Ming, Lei; Yang, Jing; Li, Saijiao.
Affiliation
  • Zhang Q; Reproductive Medical Center, Renmin Hospital of Wuhan University, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Wuhan, China.
  • He S; Reproductive Medical Center, Renmin Hospital of Wuhan University, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Wuhan, China.
  • Meng Y; Reproductive Medical Center, Renmin Hospital of Wuhan University, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Wuhan, China.
  • Yin T; Reproductive Medical Center, Renmin Hospital of Wuhan University, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Wuhan, China.
  • Ming L; Reproductive Medical Center, Renmin Hospital of Wuhan University, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Wuhan, China.
  • Yang J; Reproductive Medical Center, Renmin Hospital of Wuhan University, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Wuhan, China.
  • Li S; Reproductive Medical Center, Renmin Hospital of Wuhan University, Hubei Clinical Research Center for Assisted Fertility and Embryo Development, Wuhan, China.
Front Endocrinol (Lausanne) ; 15: 1352522, 2024.
Article in En | MEDLINE | ID: mdl-38699386
ABSTRACT

Background:

For the poor ovarian response (POR) population, the relationship between medroxyprogesterone acetate (MPA) dose in progestin-primed ovarian stimulation (PPOS) and clinical outcome is still unclear. This study aims to explore the effect of MPA dose in PPOS on clinical outcomes in POSEIDON group 3 and 4 patients with different body mass index (BMI) levels, hoping to provide clinical doctors with better options for controlled ovarian hyperstimulation (COH) programs.

Methods:

This is a retrospective analysis of 253 oocyte retrieval cycles of POSEIDON group 3 and 4 patients who underwent PPOS protocol in IVF/ICSI treatment at the Reproductive Medical Center of Renmin Hospital of Wuhan University from March 2019 to April 2022. The effects of different MPA doses (8 mg/d or 10 mg/d) on pregnancy outcomes were compared in normal BMI (18.5-24 kg/m2) and high BMI (≥24 kg/m2) patients, and multivariate logistic regression analysis was performed to analyze the factors affecting pregnancy outcomes.

Results:

For normal BMI patients, the 8-mg/d MPA group had a higher embryo implantation rate (33.78% vs. 18.97%, P = 0.012). For high BMI patients, the 10-mg/d MPA group had a higher HCG positive rate (55.00% vs. 25.00%, P = 0.028), clinical pregnancy rate (50.00% vs. 20.00%, P = 0.025), and cumulative pregnancy rate (37.74% vs. 13.79%, P = 0.023) compared with the 8-mg/d MPA group. There was no significant difference in cumulative live birth rate between the 8-mg/d and 10-mg/d MPA groups in patients with normal or high BMI. The results of multivariate logistic regression showed a significant correlation between MPA dose and cumulative pregnancy in the high BMI population (OR = 0.199, 95% CI 0.046~0.861, P = 0.031).

Conclusions:

For POR patients with high BMI, 10 mg/d of MPA in the PPOS protocol had a higher cumulative pregnancy rate than 8 mg/d of MPA, but it had no significant effect on the cumulative live birth rate.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovulation Induction / Pregnancy Outcome / Body Mass Index / Medroxyprogesterone Acetate / Pregnancy Rate Limits: Adult / Female / Humans / Pregnancy Language: En Journal: Front Endocrinol (Lausanne) Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovulation Induction / Pregnancy Outcome / Body Mass Index / Medroxyprogesterone Acetate / Pregnancy Rate Limits: Adult / Female / Humans / Pregnancy Language: En Journal: Front Endocrinol (Lausanne) Year: 2024 Document type: Article Affiliation country: